Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: Correlation with survival and clinicopathological findings

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 3, 2009, Pages 289-293

  Molaei, Mahsa ^a   Pejhan, Shervin ^a   Nayer, Babak Noori ^a   Moradi, Afshin ^a   Ghiasi, Somaye ^a   Zali, Mohamad Reza ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Colorectal cancer; Epidermal growth factor receptor; Human epidermal growth factor receptor 2; Immunohistochemistry; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; ADENOCARCINOMA; COLORECTAL TUMOR; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 62349115537     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32830b82ba     Document Type: Article

References (43)

1. Doger FK, Meteoglu I, Tuncyurek P, Okyay P, Cevikel H. Does the EGFR and VEGF expression predict the prognosis in colon cancer? Eur Surg Res 2006; 38:540-544.
2. McKay JA, Murray LJ, Curran S, Ross VG, Clark C, Murray GI, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002; 38:2258-2264.
3. Anderson WF, Umar A, Brawley OW. Colorectal carcinoma in black and white race. Cancer Metastasis Rev 2003; 22:67-82.
4. Mulsow J, Winter DC, O'Keane JC, O'Connell PR. Sentinel lymph node mapping in colorectal cancer. Br J Surg 2003; 90:659-667.
5. Fleshman JW Jr. The effect of the surgeon and the pathologist on patient survival after resection of colon and rectal cancer. Ann Surg 2002; 235:464-465.
6. Shepherd NA, Saraga EP, Love SB, Jass JR. Prognostic factors in colonic cancer. Histopathology 1989; 14:613-620.
7. Olayioye M, Neve R, Lane HA, Hynes NE. The ERBB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19:3159-3167.
8. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor. J Clin Oncol 2003; 21:2787-2799.
9. Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000; 19:3460-3469.
10. Sainsbury JR, Needham GU, Farndon JR, Needham GK, Malcolm AJ, Harris AL, et al. Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 1987; 1:1398-1402.
11. Toikkanen S, Helin H, Isola J, Joensu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow up. J Clin Oncol 1992; 10:1044-1048.
12. Salomon D, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.
13. Baselga J, Arteaga LC. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23: 2445-2459.
14. Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, et al. Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer 2006; 12:229-236.
15. Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, Ezzat A, et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 2007; 60:768-772.
16. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Assoc 1985; 53:229-232.
17. Arnaout AH, Dawson PM, Soomro S, Taylor P, Theodorou NA, Feldmann M, et al. HER2 oncoprotein expression in colorectal adenocarcinoma: an immunohistochemical study using three different antibodies. J Clin Pathol 1992; 45:726-727.
18. Kay EW, Mulcahy H, Walsh CB, Leader M, O'Donoghue D. Cytoplasmic C-erbB2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology 1994; 25:455-461.
19. Essapen S, Thomas H, Green M, De Vries N, Cook MG, Marks C, et al. The expression and prognostic significance of Her-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol 2004; 24:241-248.
20. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on cancer stage IV colon adenocarcinoma. Cancer 2001; 92:1331-1346.
21. Baselga J. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. J Clin Oncol 2002; 20: 2217-2219.
22. Waksal HW. Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 1999; 18:427-436.
23. Formento JL, Francoual M, Formento P, Etienne MC, Fischel JL, Namer M, et al. Epidermal growth factor receptor assay: validation of a single point method and application to breast cancer. Breast Cancer Res Treat 1991; 17:211-216.
24. Allred DC, Swanson PE. Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol 2000; 113:171-175.
25. Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 2006; 24: 2158-2163.
26. Mattoon D, Klein P, Lemmon MA, Lax I, Schlessinger J. The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. Pro Natl Assoc Sci U S A 2004; 101:923-928.
27. Shuch B, Mikhail M, Satagopan J, Lee P, Yee H, Chang C et al. Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol 2004; 22:4725-4729.
28. Soliman AS, Bondy ML, El-Badawy SA, Mokhtar N, Eissa S, Bayoumy S, et al. Contrasting molecular pathology of colorectal carcinoma in Egyptian and western patients. Br J Cancer 2001; 85:1037-1046.
29. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor and MDR gene expression in colorectal cancer. Cancer 1993; 71:2454-2460.
30. Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005; 16:102-108.
31. Nakae S, Shimada E, Urakawa T. Study of C-ERB-B-2 protein and epidermal growth factor receptor expression and DNA ploidy pattern in colorectal carcinoma. J Surg Oncol 1993; 54:246-251.
32. Kluftinger AM, Robinson BW, Ouenville NF, Finley RJ, Davis NL. Correlation of EGFR and C-ERBB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1992; 1:97-105.
33. Steele RJL, Kelly P, Ellul B. Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 1990; 77:1352-1354.
34. Kapitanovic S, Radosevic S, Kapitanovic M, Andelinović S, Ferencić Z, Tavassoli M, et al. The expression of p185 HER-2/neu correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997; 112:1103-1113.
35. Lazaris AC, Theodoropulos QE, Anastassopoulos P, Nakopoulou L, Panoussopoulos D, Papadimitriou K. Prognostic significance of p53 and erbb2 immunohistochemical evaluation in colorectal adenocarcinoma. Histol Histopathol 1995; 10:661-668.
36. Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, et al. Protein overexpression and gene amplification of Her-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004; 17:895-904.
37. Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD, Sinicrope FA. Her-2 receptor expression, localization and activation in colorectal cancer cell lines and human tumours. Int J Cancer 2004; 108:540-548.
38. Osako T, Miyahara M, Uchino S, Inomata M, Kitano S, Kobayashi M. Immunohistochemical study of C-ERBB2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998; 55:548-555.
39. Hemming AW, Davis NL, Kluftinger A, Robinson B, Quenville NF, Liseman B, LeRiche J. Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 1992; 51:147-152.
40. Shirai H, Ueno E, Osaki M, Tatebe S, Ito H, Kaibara N. Expression of growth factors and their receptors in human early colorectal carcinomas: immunohistochemical study. Anticancer Res 1995; 15:2889-2894.
41. Galizia G, Lieto E, Ferraraccio F, De Vita F, Castellano P, Orditura M, et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 2006; 13:823-835.
42. Koretz K, Schlag P, Moller P. Expression of epidermal growth factor receptor in normal colorectal mucosa, adenoma, and carcinoma. Virch Arch A Pathol Anat Histopathol 1990; 416:343-349.
43. Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE. Epidermal growth factor receptor, c-MET, B-Catenin, and p53 expression as prognostic indicators in stage ii colon cancer. A Tissue Microarray Study. Clin Cancer Res 2004; 10:3069-3075.